an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
Company profile
Ticker
ANTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
820606654
ANTX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
28 Mar 24
8-K
Other Events
12 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
9 Nov 23
8-K
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024
13 Sep 23
8-K
Departure of Directors or Certain Officers
7 Sep 23
424B5
Prospectus supplement for primary offering
16 Aug 23
Latest ownership filings
SC 13G
Frazier Life Sciences Public Fund, L.P.
10 Apr 24
4/A
Paul Eckburg
29 Mar 24
4/A
Lucy Day
29 Mar 24
4/A
Joshua M Eizen
29 Mar 24
4/A
Kevin Michael Krause
29 Mar 24
4/A
Sanjay Chanda
29 Mar 24
4/A
Eric Easom
29 Mar 24
4
Lucy Day
18 Mar 24
4
Joshua M Eizen
18 Mar 24
4
Kevin Michael Krause
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.62 mm | 32.62 mm | 32.62 mm | 32.62 mm | 32.62 mm | 32.62 mm |
Cash burn (monthly) | 2.73 mm | (no burn) | 6.06 mm | 5.27 mm | 3.93 mm | 3.65 mm |
Cash used (since last report) | 18.57 mm | n/a | 41.18 mm | 35.85 mm | 26.73 mm | 24.84 mm |
Cash remaining | 14.05 mm | n/a | -8.57 mm | -3.23 mm | 5.89 mm | 7.78 mm |
Runway (months of cash) | 5.1 | n/a | -1.4 | -0.6 | 1.5 | 2.1 |
Institutional ownership, Q2 2023
65.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 7 |
Closed positions | 14 |
Increased positions | 3 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 99.34 bn |
Total shares | 19.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 3.77 mm | $32.07 bn |
Adjuvant Global Health Technology Fund | 2.60 mm | $0.00 |
Biotechnology Value Fund L P | 1.56 mm | $0.00 |
BVF | 1.56 mm | $13.29 bn |
PFE Pfizer | 1.36 mm | $0.00 |
Citadel Advisors | 1.34 mm | $11.36 bn |
TCG Crossover GP I | 1.29 mm | $10.02 mm |
TCG Crossover Management | 1.29 mm | $10.96 bn |
Brii Biosciences | 1.05 mm | $0.00 |
JHG Janus Henderson | 1.00 mm | $8.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Lucy Day | Common Stock | Grant | Acquire A | No | No | 0 | 27,500 | 0.00 | 30,627 |
15 Mar 24 | Lucy Day | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 55,000 | 165.00 k | 55,000 |
15 Mar 24 | Joshua M Eizen | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 32,447 |
15 Mar 24 | Joshua M Eizen | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 60,000 | 180.00 k | 60,000 |
15 Mar 24 | Kevin Michael Krause | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 31,914 |
15 Mar 24 | Kevin Michael Krause | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 60,000 | 180.00 k | 60,000 |
15 Mar 24 | Sanjay Chanda | Common Stock | Grant | Acquire A | No | No | 0 | 27,500 | 0.00 | 28,235 |
15 Mar 24 | Sanjay Chanda | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 55,000 | 165.00 k | 55,000 |
15 Mar 24 | Paul Eckburg | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 51,416 |
15 Mar 24 | Paul Eckburg | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 60,000 | 180.00 k | 60,000 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Apr 24
JMP Securities Upgrades AN2 Therapeutics to Market Outperform, Announces $6 Price Target
2 Apr 24
AN2 Therapeutics Q4 EPS $(0.57) Beats $(0.76) Estimate
28 Mar 24
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
13 Feb 24
Leerink Partners Downgrades AN2 Therapeutics to Market Perform, Lowers Price Target to $7
13 Feb 24
Press releases
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
22 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
7 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
3 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
24 Feb 24